NRx Pharmaceuticals (NASDAQ:NRXP) Given “Buy” Rating at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a research report sent to investors on Monday,Benzinga reports. They currently have a $34.00 price target on the stock.

A number of other research firms also recently issued reports on NRXP. HC Wainwright lifted their price objective on shares of NRx Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. Wall Street Zen upgraded shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, November 23rd. Ascendiant Capital Markets reissued a “buy” rating and set a $48.00 price target (up from $47.00) on shares of NRx Pharmaceuticals in a research report on Friday, January 2nd. Weiss Ratings restated a “sell (e+)” rating on shares of NRx Pharmaceuticals in a report on Monday, December 29th. Finally, Zacks Research raised shares of NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, March 2nd. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, NRx Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $38.00.

NRx Pharmaceuticals Trading Up 1.8%

Shares of NRx Pharmaceuticals stock opened at $1.73 on Monday. The company has a market capitalization of $55.14 million, a P/E ratio of -0.74 and a beta of 1.97. The stock has a fifty day simple moving average of $2.06 and a 200 day simple moving average of $2.49. NRx Pharmaceuticals has a 12-month low of $1.58 and a 12-month high of $3.84.

Institutional Investors Weigh In On NRx Pharmaceuticals

A number of hedge funds have recently made changes to their positions in NRXP. Ethos Financial Group LLC purchased a new position in shares of NRx Pharmaceuticals in the 3rd quarter worth about $39,000. Sjbenen Advisory LLC purchased a new stake in NRx Pharmaceuticals during the fourth quarter worth about $41,000. One Wealth Management Investment & Advisory Services LLC increased its holdings in NRx Pharmaceuticals by 86.1% during the third quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock worth $92,000 after buying an additional 12,950 shares during the last quarter. Global Retirement Partners LLC bought a new stake in NRx Pharmaceuticals in the fourth quarter worth about $107,000. Finally, Two Sigma Investments LP raised its position in NRx Pharmaceuticals by 66.4% in the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after acquiring an additional 20,880 shares during the period. 4.27% of the stock is currently owned by institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.